IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New injection aims to tame kidney disease
Disease control Not yet recruitingThis Phase 2 trial tests an injection called CM313 in 106 people with IgA nephropathy, a kidney disease. The study looks at safety and whether the drug can help control the disease. Participants will receive either CM313 or a placebo, and researchers will monitor side effects and…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
New drug BHV-1400 aims to protect kidneys in IgA nephropathy
Disease control Not yet recruitingThis Phase 3 trial tests whether BHV-1400 can safely reduce protein in the urine and preserve kidney function in 420 adults with IgA nephropathy. Participants are randomly assigned to receive either the drug or a placebo by injection. The main goal is to see if BHV-1400 lowers pr…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
New drug trial aims to protect Kids' kidneys from IgA nephropathy
Disease control Not yet recruitingThis phase 3 trial tests the drug atrasentan in 28 children aged 2 to 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The study measures whether atrasentan reduces protein in the urine, a sign of kidney damage, over 36 weeks. All participants receive th…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
Can a maintenance drug stop IgA kidney disease relapse?
Disease control Not yet recruitingThis study tests whether a low dose of Nefecon (8 mg) can prevent proteinuria relapse in people with IgA nephropathy who have already responded to treatment. About 288 adults who completed 9 months of Nefecon therapy and have low protein levels will take either Nefecon or a place…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE4 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 22, 2026 11:54 UTC
-
New hope for kidney disease: experimental drug targets protein leak
Disease control Not yet recruitingThis early-stage trial tests a drug called NM8074 in 10 adults with IgA Nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug safely reduces protein in the urine, a sign of kidney damage, after 99 days of treatment. Participants must have a…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: NovelMed Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New study to track how kidney disease drugs work in real life
Knowledge-focused Not yet recruitingThis study will observe 80 adults with IgA nephropathy who are prescribed iptacopan or atrasentan as part of their routine care. Researchers will collect data on patient profiles, treatment patterns, and clinical outcomes over 24 months. The goal is to understand how these drugs …
Matched conditions: IGA NEPHROPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 23, 2026 23:31 UTC